ALT
Price
$3.90
Change
+$0.03 (+0.78%)
Updated
Jul 1, 11:53 AM (EDT)
Capitalization
313.88M
37 days until earnings call
IDYA
Price
$21.02
Change
-$0.35 (-1.64%)
Updated
Jun 30 closing price
Capitalization
1.84B
42 days until earnings call
Interact to see
Advertisement

ALT vs IDYA

Header iconALT vs IDYA Comparison
Open Charts ALT vs IDYABanner chart's image
Altimmune
Price$3.90
Change+$0.03 (+0.78%)
Volume$15.3K
Capitalization313.88M
IDEAYA Biosciences
Price$21.02
Change-$0.35 (-1.64%)
Volume$866.73K
Capitalization1.84B
ALT vs IDYA Comparison Chart in %
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. IDYA commentary
Jul 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a StrongBuy and IDYA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 01, 2025
Stock price -- (ALT: $3.87 vs. IDYA: $21.02)
Brand notoriety: ALT and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 335% vs. IDYA: 68%
Market capitalization -- ALT: $313.88M vs. IDYA: $1.84B
ALT [@Biotechnology] is valued at $313.88M. IDYA’s [@Biotechnology] market capitalization is $1.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 5 TA indicator(s) are bullish while IDYA’s TA Score has 4 bullish TA indicator(s).

  • ALT’s TA Score: 5 bullish, 4 bearish.
  • IDYA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ALT is a better buy in the short-term than IDYA.

Price Growth

ALT (@Biotechnology) experienced а -44.64% price change this week, while IDYA (@Biotechnology) price change was -1.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.11%. For the same industry, the average monthly price growth was +32.18%, and the average quarterly price growth was +3.41%.

Reported Earning Dates

ALT is expected to report earnings on Aug 07, 2025.

IDYA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (-1.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($1.84B) has a higher market cap than ALT($314M). IDYA YTD gains are higher at: -18.210 vs. ALT (-46.325). ALT has higher annual earnings (EBITDA): -90.75M vs. IDYA (-356.46M). IDYA has more cash in the bank: 693M vs. ALT (150M). ALT has less debt than IDYA: ALT (1.59M) vs IDYA (26M). IDYA has higher revenues than ALT: IDYA (7M) vs ALT (20K).
ALTIDYAALT / IDYA
Capitalization314M1.84B17%
EBITDA-90.75M-356.46M25%
Gain YTD-46.325-18.210254%
P/E RatioN/AN/A-
Revenue20K7M0%
Total Cash150M693M22%
Total Debt1.59M26M6%
FUNDAMENTALS RATINGS
ALT vs IDYA: Fundamental Ratings
ALT
IDYA
OUTLOOK RATING
1..100
562
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
62
Fair valued
PROFIT vs RISK RATING
1..100
10069
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
9553
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (62) in the null industry is somewhat better than the same rating for ALT (97) in the Miscellaneous Commercial Services industry. This means that IDYA’s stock grew somewhat faster than ALT’s over the last 12 months.

IDYA's Profit vs Risk Rating (69) in the null industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that IDYA’s stock grew similarly to ALT’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as ALT (97) in the Miscellaneous Commercial Services industry. This means that IDYA’s stock grew similarly to ALT’s over the last 12 months.

IDYA's Price Growth Rating (53) in the null industry is somewhat better than the same rating for ALT (95) in the Miscellaneous Commercial Services industry. This means that IDYA’s stock grew somewhat faster than ALT’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that IDYA’s stock grew similarly to ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTIDYA
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 6 days ago
76%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 1 day ago
77%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
73%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OTGAX9.310.09
+0.98%
OTG Latin America A Shares
POSAX8.81N/A
N/A
Principal Global Real Estate Sec A
GLVCX73.70N/A
N/A
Invesco Global Focus C
SMVSX26.17N/A
N/A
Invesco Small Cap Value R6
BGPKX13.77-0.01
-0.07%
Baillie Gifford Developed EAFE All Cap K

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-1.64%
IMNM - IDYA
60%
Loosely correlated
+6.04%
CGON - IDYA
60%
Loosely correlated
+0.19%
NRIX - IDYA
58%
Loosely correlated
-2.15%
SYRE - IDYA
56%
Loosely correlated
-1.64%
XENE - IDYA
56%
Loosely correlated
-3.40%
More